Short answer
Boston Scientific (BSX) filed an 8-K current report with the SEC on May 18, 2026 reporting Item 8.01 (Other Events). $1.5B investment acquired 33.75% of MiRus and an exclusive option for TAVR-Structural Heart NewCo.
Boston Scientific 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $1.5B investment acquired 33.75% of MiRus and an exclusive option for TAVR-Structural Heart NewCo
- Call Option could require $3.0B in additional payments following clinical and regulatory milestones
- Investment provides exposure to MiRus’s FDA-authorized STAR trial for its Siegel TAVR system
- Failure to fund or exercise the option could forfeit or reduce Boston Scientific’s MiRus stake by approximately 75%
- Additional sales-based payments and optional mitral and tricuspid valve assets could increase future transaction economics
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Boston Scientific 8-K filings
Get the next BSX 8-K as it lands
Follow BSX for push alerts, or ask the research agent what this filing means.